Form 4: Compass Therapeutics Executive Granted Stock Options

Jonathan Anderman, Sr VP, Gen Counsel & Corp Sec of Compass Therapeutics, was granted stock options to purchase 300,000 shares.

Summary

• Jonathan Anderman, a Senior Vice President, General Counsel, and Corporate Secretary at Compass Therapeutics, Inc. (CMPX), was granted stock options.
• The transaction occurred on August 13, 2024.
• Anderman received options to purchase 300,000 shares of Compass Therapeutics common stock at an exercise price of $1.20.
• The options vest in 48 substantially equal monthly installments beginning September 13, 2024, and expire on August 13, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine grant of stock options. It's positive for the executive but doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Compass Therapeutics.
• Comparable companies such as Arcus Biosciences or Gritstone Bio also utilize stock options to incentivize their leadership teams.
• The vesting schedule of 48 months is also typical in the industry, aligning with long-term value creation.

Stakeholder Impact

• Shareholders may view the option grant as a way to align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates